Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.

William J Taylor, Nicola Dalbeth, Sara K Tedeschi, Abhishek Abhishek, Dorcas Beaton, Peter Tugwell, Sabrina M Nielsen, Fabio Becce, Tristan Pascart, N Lawrence Edwards, Lisa K Stamp, Cesar Diaz-Torne, Ken Cai, Georgios Filippou, Ann K Rosenthal, Geraldine M McCarthy, Jasvinder A Singh, Beverley Shea, Robin Christensen, David Grossberg, Owen Hensey, Yiling Zhang, Amy Fuller

Journal: Seminars in arthritis and rheumatism 2021;51(4):946-950

PMID: 34140183

Free Full Text on Archivio Istituzionale della Ricerca Unimi - Access Free Full Text View on PubMed

Abstract

INTRODUCTION

Although calcium pyrophosphate deposition (CPPD) is common, there are no published outcome domains or validated measurement instruments for CPPD studies. In this paper, we describe the framework for development of the Outcome Measures in Rheumatology (OMERACT) CPPD Core Domain Sets.

METHODS

The OMERACT CPPD working group performed a scoping literature review and qualitative interview study. Generated outcomes were presented at the 2020 OMERACT CPPD virtual Special Interest Group (SIG) meeting with discussion focused on whether different core domain sets should be developed for different calcium pyrophosphate deposition (CPPD) clinical presentations and how the future CPPD Core Domain Set may overlap with already established osteoarthritis (OA) domains. These discussions informed development of a future work plan for development of the OMERACT CPPD Core Domain Sets.

FINDINGS

Domains identified from a scoping review of 112 studies and a qualitative interview study of 36 people (28 patients with CPPD, 7 health care professionals, one stakeholder) were mapped to core areas of OMERACT Filter 2.1. The majority of SIG participants agreed there was need to develop separate core domain sets for "short term" and "long term" studies of CPPD. Although CPPD + OA is common and core domain sets for OA have been established, participants agreed that existing OA core domain sets should not influence the development of OMERACT core domain sets for CPPD. Prioritization exercises (using Delphi methodology) will consider 40 potential domains for short term studies of CPPD and 47 potential domains for long term studies of CPPD.

CONCLUSION

Separate OMERACT CPPD Core Domain Sets will be developed for "short term" studies for an individual flare of acute CPP crystal arthritis and for "long term" studies that may include participants with any clinical presentation of CPPD (acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and/or CPPD + OA).

Address: Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Auckland, New Zealand. Electronic address: [email protected].; Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom; Nottingham NIHR-BRC, Nottingham, United Kingdom.; Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Auckland, New Zealand.; The Central Remedial Clinic, Dublin, Ireland.; Holy Cross Hospital, Silver Spring, MD, United States; Suburban Hospital, Bethesda, MD, United States.; Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark.; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.; Medicine Service, VA Medical Center, Birmingham, AL, United States; Department of Medicine at the School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, United States; Department of Epidemiology at the UAB School of Public Health, Birmingham, AL, United States.; University College Dublin, Dublin, Ireland.; Department of Medicine, Medical College of Wisconsin, Milwaukee, United States.; Rheumatology Unit, ASST-Fatebenefratelli L, Sacco University Hospital, University of Milan, Italy.; Department of Medicine, University of Otago, Wellington, New Zealand.; Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autonòma de Barcelona, Spain.; Department of Medicine, University of Otago, Christchurch, New Zealand.; Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, United States.; Department of Rheumatology, Hospital Saint-Philbert, Lille Catholic University, Lille, France.; Department of Diagnostic and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Department of Medicine, University of Ottawa, Ottawa, Canada.; Institute for Work and Health, University of Toronto, Toronto, Canada.; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, United States.

DOI: 10.1016/j.semarthrit.2021.04.019

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/osteoarthritis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Calcinosis, Calcium Pyrophosphate, Chondrocalcinosis, Humans, Osteoarthritis, Rheumatology